Noxopharm Ltd has released a press release.
US company demonstrates strong Sofra potential
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- June 2025 Quarterly Activities Report and Appendix 4C
- HERACLES clinical trial - Update 1
- First SOF-SKN dose in HERACLES clinical trial
- Promising Sofra results from overseas company
- Green light for HERACLES clinical trial
Later from Noxopharm
- HERACLES clinical trial Update 2
- HERACLES clinical trial Update 3
- Appendix 4E Preliminary Final Report
- HERACLES clinical trial Update 4
- Extension of Convertible Notes and Funding
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm